Science News

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced positive results of the Phase 3 EPCORE® FL-1 trial evaluating subcutaneous epcoritamab, a bispecific antibody, in combination with rituximab and lenalidomide (R2) versus R2 alone for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The study met its dual primary endpoints of overall response rate (ORR, p-value < 0.0001) and progression-free survival (PFS, HR 0.21, p-valu...

ROOTSTOWN, Ohio--(BUSINESS WIRE)--BioMendics, a clinical-stage biopharmaceutical company focused on rare skin diseases, today announced the launch of the TAMES-02 clinical trial—a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of TolaSure™, a first-in-class topical therapy for patients with generalized intermediate to severe Epidermolysis Bullosa Simplex (EB Simplex). EB Simplex is a rare, inherited skin disorder that causes painful blistering...

DETROIT--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, will convene breast cancer survivors, those living with metastatic breast cancer (MBC) and supporters at the 2025 Susan G. Komen Detroit Race for the Cure. This impactful event unites our community and raises money for the mission of Komen, supporting those affected by breast cancer. Komen aims to raise over $300,000 at the Detroit Race for the Cure, generating critical funds that allow Komen to continue...

SAN FRANCISCO--(BUSINESS WIRE)--Planet Labs PBC (NYSE: PL), a leading provider of daily data and insights about Earth, today announced that it will participate in Morgan Stanley’s 13th Annual Laguna Conference, which is being held September 10-12, 2025. The company will be available for 1x1 meetings with investors. If interested in attending this event or scheduling a meeting with management, we recommend reaching out to your contact at Morgan Stanley to learn more. About Planet Planet is a lea...

WALTHAM, Mass.--(BUSINESS WIRE)--The path to publication for medical researchers can be a long process, in which scholars seek to maximize the profile of their research with global accessibility, increased downloads, and higher citations. To help broaden readership and amplify authors’ influence within the health research community, Wolters Kluwer Health announces the introduction of Lippincott Author Portal and Journal Recommender, key tools to boost the effectiveness and reach of new research...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--ThinkBio.Ai® and UST Partner to Strengthen AI Enablement Capabilities for Biopharma and Healthcare Organizations....

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity Life Sciences, a leader in advisory, insights and analytics for the life sciences industry, today announced its recognition as a Leader in Everest Group’s 2025 PEAK Matrix® for Life Sciences AI and Analytics. Trinity Life Sciences was one of only ten companies to achieve Leader status. "We are thrilled to be recognized as a Leader in Everest Group's 2025 PEAK Matrix® for Life Sciences AI and Analytics," said Leslie Orne, President and CEO of Trinity Life...

NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (OTCQB: QTIH) (“QT Imaging” or the “Company”), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced financial results for the three and six months ended June 30, 2025, and provided a business update. “We are pleased to report that the strong business momentum from the first quarter carried through Q2, and in many ways, we are even more energized by the signi...

TAMPERE, Finland--(BUSINESS WIRE)--Ancient DNA research led by Vapriikki produced new insights into kinship, health, and population continuity in medieval and early modern Finland....

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the second quarter ended June 30, 2025, and provided an update on recent company developments. “The second quarter marked a pivotal step forward as we advanced our lead program, RLYB116, into a confirmatory PK/PD study, which is an important mi...